COVID-19 With Preexisting Hypercoagulability Digestive Disease

Frontiers in Medicine

article

Mingshan Jiang¹  Jingxi Mu¹  Silan Shen¹  Hu Zhang¹ 

[1] Department of Gastroenterology, West China Hospital, Sichuan University;Center for Inflammatory Bowel Disease, West China Hospital, Sichuan University;Laboratory of Inflammatory Bowel Disease, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University

关键词: coronavirus disease 2019;    hypercoagulability;    thromboembolism;    SARS-CoV-2;    inflammatory bowel disease;   

DOI  :  10.3389/fmed.2020.587350

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

The outbreak of coronavirus disease of 2019 (COVID-19) has become a global public health and economic crisis. The advent of hypercoagulability and thrombotic complications can substantially influence the prognosis of COVID-19 patients. In this review, we elaborate on the clinical findings, potential underlying pathogenesis, and therapeutic strategy of hypercoagulability and thromboembolism in COVID-19, particularly focusing on the COVID-19 patients with preexisting digestive hypercoagulability disease.

【 授权许可】

CC BY